ReviewClinical microbiology reviews1999
Intranasal antibody prophylaxis for protection against viral disease.
Review in Clinical microbiology reviews, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19.Frontiers in immunology · 2022Trial
- Drum Filling of Thin-Film Freeze-Dried Monoclonal Antibody Powder in UniDose Powder Nasal Spray System.Pharmaceutical research · 2025Article
- Use of Immunoglobulin Y Antibodies: Biosensor-based Diagnostic Systems and Prophylactic and Therapeutic Drug Delivery Systems for Viral Respiratory Diseases.Current topics in medicinal chemistry · 2024Review
- COVID-19 prophylaxis with immunoglobulin Y (IgY) for the world population: The critical role that governments and non-governmental organizations can play.Journal of global health · 2022Article
- Exploring the Role of Antiviral Nasal Sprays in the Control of Emerging Respiratory Infections in the Community.Infectious diseases and therapy · 2022Article
- Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.Med (New York, N.Y.) · 2022Article
- Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.Scientific reports · 2022Article
- Article
- Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections.Applied microbiology and biotechnology · 2021Review
- Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?International journal of molecular sciences · 2021Review
- Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.Frontiers in immunology · 2021Review
- IgY - turning the page toward passive immunization in COVID-19 infection (Review).Experimental and therapeutic medicine · 2020Review
- Article
- Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-A-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans.The Journal of infectious diseases · 2020Article
- Differential Recognition of Diet-Derived Neu5Gc-Neoantigens on Glycan Microarrays by Carbohydrate-Specific Pooled Human IgG and IgA Antibodies.Bioconjugate chemistry · 2019Article
- IgY antibodies for the immunoprophylaxis and therapy of respiratory infections.Human vaccines & immunotherapeutics · 2019Review
- Oral Passive Immunization With Plasma-Derived Polyreactive Secretory-Like IgA/M Partially Protects Mice Against Experimental Salmonellosis.Frontiers in immunology · 2018Article
- Novel high-throughput cell-based hybridoma screening methodology using the Celigo Image Cytometer.Journal of immunological methods · 2017Article
- Review
- Production and Characterization of Human Monoclonal Antibodies from the Cells of A(H1N1)pdm2009 Influenza Virus Infected Indian Donors.Procedia in vaccinology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For more than a century, antibody has been used for passive parenteral immunization against viral and bacterial pathogens. This approach has been successful for prevention of viral respiratory infection and has led to testing of intranasal or aerosol delivery of antibody to passively immunize the respiratory tract mucosal surface. Mucosal delivery may be advantageous because it allows the antibody to neutralize the virus particles before they initiate infection and because it concentrates the antibody where viral replication takes place. Animal studies have shown the feasibility of passive intranasal immunization against a number of respiratory tract viruses. Development of nasal antibody treatments for humans is under way, and early clinical studies have confirmed that this approach is safe and can be used to prevent respiratory tract disease. Polyclonal human immunoglobulin from pooled plasma preparations can be used to provide broad protection against a number of different pathogens, while monoclonal antibodies or their fragments can be used to target specific viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.